CDF
Keytruda/chemo combo recommended for first-line lung cancer via Cancer Drugs Fund
August 8, 2019Sales and Marketing CDF, Cancer, MSD, NHS, NICE, UK, keytruda, lung cancer, pharma
MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy …
BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund
April 5, 2019Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, Kidney cancer, NICE, UK, Yervoy, opdivo
NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to …
NICE recommends Eli Lilly’s Verzenio in combination with Fulvestrant for breast cancer
April 2, 2019Manufacturing and Production CDF, Cancer, NICE, breast cancer, britain, oncology
Britain’s cost effectiveness body, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly’s Verzenio (abemaciclib) in …
Cancer Drugs Fund to offer MSD’s Keytruda for lung cancer
November 22, 2018Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NICE, UK, keytruda, pharma
MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces …
BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer
October 13, 2017Sales and Marketing BMS, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, NICE, opdivo, pharma, pharmaceutical
Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for …
NICE gives final draft guidance on two key cancer drugs
October 12, 2017Sales and Marketing Bayer, CDF, Cancer, Cancer Drugs Fund, Erivedge, NICE, Roche, Stivarga
NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the …
Roche antibody becomes first of its kind authorised for blood cancer
July 26, 2017Research and Development, Sales and Marketing CDF, Cancer, NICE, drugs, lymphoma, pharma, pharmaceutical Roche
NICE has announced its decision to make Roche’s Gazyvaro available via the Cancer Drugs Fund (CDF) in combination with chemotherapy …
Price cuts bring 14 Cancer Drugs Fund treatments into routine NHS use
March 3, 2017Medical Communications, Sales and Marketing CDF, NICE
NICE has revealed that it has reached the halfway point in its review of the old Cancer Drugs Fund (CDF) …
NICE recommends Novartis’ previously CDF-exclusive kidney cancer treatment
January 13, 2017Medical Communications, Sales and Marketing Afinitor, CDF, NICE, Novartis, everolimus
In a reappraisal decision by NICE, everolimus (Novartis’ Afinitor) has been recommended for the treatment of advanced renal cell carcinoma …
Insider interview: Roche discusses efficacy of CDF and NICE
November 25, 2016Medical Communications, Sales and Marketing CDF, NICE, Roche
Deborah Lancaster, Head of Market Access at Roche, discusses, in the latest issue of Pharmafile, the efficacy of the National …
NICE and the CDF: Are they still up to scratch?
October 4, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE
Originally published in the October issue of Pharmafocus, Matt Fellows explores medical and pharmaceutical opinion of the divisive institute to …
The September issue of Pharmafocus is now live!
August 31, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myer's Squibb, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, Cloud Computing, Pharmafocus, Pharmafocus new issue, brexit, clinical trial transparaency, opdivo
The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial …
NICE approves lung cancer and leukaemia treatments
August 24, 2016Research and Development, Sales and Marketing Alimta, CDF, NICE, bosulif, bosutinib, pemetrexed
The National Institute for Health and Care Excellence (NICE) has issued its approval of two drugs for routine use on …
Bayer’s liver cancer drug not cost-effective, says NICE
August 19, 2016Medical Communications, Sales and Marketing Bayer, CDF, NICE, Nexavar, lung cancer
NICE has deemed Bayer’s liver cancer drug Nexavar (sorafenib) as not cost-effective. The drug is currently available on the Cancer …
Top ten stories in the pharmaceutical industry this week
August 5, 2016Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten
It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …
